Precio de WinWIN

Menu BioSpace logo Show Search Bluebird’s Newly Approved SCD Gene Therapy Faces Rough Road with Hefty Price Tag, Boxed Warning December 11, 2023 | 2 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print Pictured: Illustration showing sickle cells in the Pictured: Illustration showing sickle cells in the These factors, along with bluebird bio’s failure to receive a priority review voucher, all hurt the company’s stock price following Lyfgenia’s approval. Pictured: Illustration of sickle cells in the bloodstream/iStock, Artur Plawgo Despite winning FDA approval on Friday for its sickle cell disease gene therapy Lyfgenia (lovotibeglogene autotemcel), bluebird bio’s investors were less than bullish on the company. The Massachusetts-based biotech closed the day down nearly 35%. Much of the negative share reaction could have been driven by Lyfgenia’s list price. Shortly after its regulatory win, bluebird announced that the gene therapy would have a wholesale acquisition cost of $3.1 million. In its news announcement, bluebird said it arrived at this price “in recognition of the value the therapy may deliver through robust and sustained clinical benefits and the estimated lifetime impact,” including savings from lower healthcare utilization, patients’ future earnings and their life opportunities. By comparison, Vertex Pharmaceuticals’ and CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel), which was approved on the same day as Lyfgenia, will go for $2.2 million. Casgevy is a CRISPR-based gene edited therapy, is also indicated for sickle cell disease (SCD) and will likely be a strong competitor for Lyfgenia. Over the weekend, at the 65th Annual Meeting & Exposition of the American Society of Hematology, experts were cautiously optimistic about what the dual approvals of Casgevy and Lyfgenia might mean for patients, STAT News reported. However, many expressed their confusion, if not shock, at bluebird’s pricing. “For two therapies which do pretty much the same thing and are targeting exactly the same population, a price tag that’s $1 million apart, I think, is a major deciding factor for many patients and providers and even insurance programs,” Akshay Sharma, who treats pediatric SCD patients at St. Jude Children’s Research Hospital, told STAT. “It’s baffling to me why Bluebird Bio priced their therapy so high — or maybe Vertex priced theirs low, I don’t know,” Sharma said. Also potentially contributing to bluebird’s drop on Friday is Lyfgenia’s boxed warning, which flags instances of hematologic malignancies in patients who had been treated with the gene therapy. Additionally, bluebird failed to secure an FDA priority review voucher, which it had planned to sell to Novartis for $103 million in a bid to improve its cash position. In its third-quarter financial report, bluebird said that it had $227 million in cash, cash equivalents, marketable securities and restricted cash, which would be enough to support its operations only through the second quarter of 2024. Seemingly lost in the discussion about Lyfgenia’s pricing are new long-term follow-up data, which bluebird posted on Saturday. Over five years of follow-up, 94% patients treated with the gene therapy achieved complete resolution of severe vaso-occlusive events, while 88.2% saw complete resolution of all vaso-occlusive events.

$SONIC The wait is finally over, and SONIC is now live! This highly anticipated launch has generated significant excitement in the cryptocurrency community, with many investors and traders eager to get in on the action. *Bullish or Bearish: The Debate Begins* As SONIC begins its journey, the question on everyone's mind is: will it be bullish or bearish? Will the token's value skyrocket, or will it experience a downturn? To answer this question, let's delve into the world of SONIC and explore its potential. *Understanding SONIC* SONIC is a revolutionary new token that's designed to disrupt the status quo. With its unique features and innovative approach, SONIC is poised to make a significant impact in the cryptocurrency market. *Key Features of SONIC* So, what sets SONIC apart from other tokens? Here are some of its key features: - *Decentralized*: SONIC is built on a decentralized platform, ensuring that it's secure, transparent, and resistant to censorship. - *Community-driven*: SONIC is driven by a passionate community of supporters who are dedicated to its success. - *Innovative technology*: SONIC utilizes cutting-edge technology to provide fast, secure, and efficient transactions. *Join the Conversation and Share 19,200 SONIC* To celebrate the launch of SONIC, we're inviting you to join the conversation and share your thoughts on its potential. As a special incentive, we're giving away 19,200 SONIC to participants! *How to Participate* To participate in the giveaway and join the conversation, simply: 1. Follow our social media channels. 2. Share your thoughts on SONIC's potential (bullish or bearish). 3. Tag three friends who might be interested in SONIC. *The Future of SONIC* As SONIC begins its journey, it's clear that it has tremendous potential. With its innovative technology, community-driven approach, and decentralized platform, SONIC is poised to make a significant impact in the cryptocurrency market. *Conclusion* The launch of SONIC marks an exciting new chapter in the world of cryptocurrency. Whether you're a seasoned investor or just starting out, SONIC is definitely worth keeping an eye on. Join the conversation, share your thoughts, and don't miss out on the opportunity to win 19,200 SONIC!

Menu BioSpace logo Show Search Bluebird’s Newly Approved SCD Gene Therapy Faces Rough Road with Hefty Price Tag, Boxed Warning December 11, 2023 | 2 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print Pictured: Illustration showing sickle cells in the Pictured: Illustration showing sickle cells in the These factors, along with bluebird bio’s failure to receive a priority review voucher, all hurt the company’s stock price following Lyfgenia’s approval. Pictured: Illustration of sickle cells in the bloodstream/iStock, Artur Plawgo Despite winning FDA approval on Friday for its sickle cell disease gene therapy Lyfgenia (lovotibeglogene autotemcel), bluebird bio’s investors were less than bullish on the company. The Massachusetts-based biotech closed the day down nearly 35%. Much of the negative share reaction could have been driven by Lyfgenia’s list price. Shortly after its regulatory win, bluebird announced that the gene therapy would have a wholesale acquisition cost of $3.1 million. In its news announcement, bluebird said it arrived at this price “in recognition of the value the therapy may deliver through robust and sustained clinical benefits and the estimated lifetime impact,” including savings from lower healthcare utilization, patients’ future earnings and their life opportunities. By comparison, Vertex Pharmaceuticals’ and CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel), which was approved on the same day as Lyfgenia, will go for $2.2 million. Casgevy is a CRISPR-based gene edited therapy, is also indicated for sickle cell disease (SCD) and will likely be a strong competitor for Lyfgenia. Over the weekend, at the 65th Annual Meeting & Exposition of the American Society of Hematology, experts were cautiously optimistic about what the dual approvals of Casgevy and Lyfgenia might mean for patients, STAT News reported. However, many expressed their confusion, if not shock, at bluebird’s pricing. “For two therapies which do pretty much the same thing and are targeting exactly the same population, a price tag that’s $1 million apart, I think, is a major deciding factor for many patients and providers and even insurance programs,” Akshay Sharma, who treats pediatric SCD patients at St. Jude Children’s Research Hospital, told STAT. “It’s baffling to me why Bluebird Bio priced their therapy so high — or maybe Vertex priced theirs low, I don’t know,” Sharma said. Also potentially contributing to bluebird’s drop on Friday is Lyfgenia’s boxed warning, which flags instances of hematologic malignancies in patients who had been treated with the gene therapy. Additionally, bluebird failed to secure an FDA priority review voucher, which it had planned to sell to Novartis for $103 million in a bid to improve its cash position. In its third-quarter financial report, bluebird said that it had $227 million in cash, cash equivalents, marketable securities and restricted cash, which would be enough to support its operations only through the second quarter of 2024. Seemingly lost in the discussion about Lyfgenia’s pricing are new long-term follow-up data, which bluebird posted on Saturday. Over five years of follow-up, 94% patients treated with the gene therapy achieved complete resolution of severe vaso-occlusive events, while 88.2% saw complete resolution of all vaso-occlusive events.

$MTOS _MTOS is Live: A New Era Begins_ The wait is over, and MTOS is finally live! This highly anticipated launch has generated significant buzz in the cryptocurrency community, with many investors and traders eager to get in on the action. _Bullish or Bearish: The Debate Begins_ As MTOS begins its journey, the question on everyone's mind is: will it be bullish or bearish? Will the token's value skyrocket, or will it experience a downturn? To answer this question, let's delve into the world of MTOS and explore its potential. _Understanding MTOS_ MTOS is a revolutionary new token that's designed to disrupt the status quo. With its unique features and innovative approach, MTOS is poised to make a significant impact in the cryptocurrency market. _Key Features of MTOS_ So, what sets MTOS apart from other tokens? Here are some of its key features: - _Decentralized_: MTOS is built on a decentralized platform, ensuring that it's secure, transparent, and resistant to censorship. - _Community-driven_: MTOS is driven by a passionate community of supporters who are dedicated to its success. - _Innovative technology_: MTOS utilizes cutting-edge technology to provide fast, secure, and efficient transactions. _Join the Conversation and Share 106,656 MTOS_ To celebrate the launch of MTOS, we're inviting you to join the conversation and share your thoughts on its potential. As a special incentive, we're giving away 106,656 MTOS to participants! _How to Participate_ To participate in the giveaway and join the conversation, simply: 1. Follow our social media channels. 2. Share your thoughts on MTOS's potential (bullish or bearish). 3. Tag three friends who might be interested in MTOS. _The Future of MTOS_ As MTOS begins its journey, it's clear that it has tremendous potential. With its innovative technology, community-driven approach, and decentralized platform, MTOS is poised to make a significant impact in the cryptocurrency market. _Conclusion_ The launch of MTOS marks an exciting new chapter in the world of cryptocurrency. Whether you're a seasoned investor or just starting out, MTOS is definitely worth keeping an eye on. Join the conversation, share your thoughts, and don't miss out on the opportunity to win 106,656 MTOS!

My dear friend, today you became a part of the ever-changing story of the crypto world—a realm where ambition and volatility walk hand in hand. You placed your trust in $CATGOLD, believing in its potential to shine, yet within 24 hours, the market tested your resolve, reducing your $1,000 investment to $782. This journey is a reminder that crypto is not just about quick gains—it’s about strategy, patience, and belief in the bigger picture. $CATGOLD, like many emerging tokens, holds promise within the blockchain gaming space. Its connection to the TON ecosystem and its mission to bridge gaming and finance are the reasons many believe in its long-term potential. But the key lies in understanding the waves of the market. If you had waited, as we discussed, until February, the story might have unfolded differently. Yet every trade, whether a win or a loss, is a valuable lesson. Here’s what $CATGOLD and this experience can teach you about navigating the crypto waters: 1. Patience Brings Prosperity Crypto projects like $CATGOLD often face initial turbulence before stabilizing and realizing their potential. Trust the process and allow the project time to grow and deliver on its promises. 2. Timing is Everything The crypto market is as much about strategy as it is about opportunity. Research and holding onto your conviction during temporary dips can be more rewarding than impulsive trades. 3. Stay Aligned with the Vision Tokens like $CATGOLD thrive on community support and utility expansion. Keep an eye on the roadmap, project milestones, and market sentiment. Confidence in a project comes from understanding its foundation. 4. Risk Management Matters Volatility is the heartbeat of crypto. Always invest what you can afford to lose, and diversify your holdings to mitigate risks. 5. Learn and Evolve Every loss is a stepping stone. Take this as a moment to reflect, refine your strategy, and become a more informed trader. The $CATGOLD story is far from over. Projects like this have the potential to surprise us with their resilience and innovation. For now, take this experience as a valuable chapter in your crypto journey and remember—gold often glimmers brightest after the dust settles. Here’s to your future success and smarter strategies ahead. The next time we look at $CATGOLD, let it be a symbol of growth, not just in the market, but within you as well. 🌟